Core Viewpoint - Bavarian Nordic A/S announces the resignation of CEO Paul Chaplin for personal reasons, with a transition plan in place for the remainder of 2026 [1][3] Company Leadership Transition - Paul Chaplin has been with Bavarian Nordic since 1999 and became CEO in 2014, significantly contributing to the development of smallpox and mpox vaccines [2] - The Board of Directors has initiated the search for a new CEO while Chaplin will remain in his role until a successor is found [1][3] Company Growth and Achievements - Under Chaplin's leadership, Bavarian Nordic transformed from a small research-based company to a large vaccine manufacturer with strong commercial operations [2] - The company has successfully expanded its portfolio through strategic acquisitions and has established itself as a preferred supplier of vaccines to governments [4]

Core Insights - Bavarian Nordic A/S reported preliminary financial results for 2025, with revenue of DKK 6,244 million, exceeding the latest guidance of approximately DKK 6,000 million [1][2] - The company achieved an EBITDA of DKK 2,542 million, resulting in an EBITDA margin of 41%, surpassing the latest guidance of approximately 40% [2][4] Financial Performance - Revenue breakdown for 2025 includes DKK 3,105 million from Public Preparedness and DKK 2,963 million from Travel Health, with Travel Health showing a 30% year-over-year growth [5][7] - The company’s core vaccines, rabies and TBE, contributed significantly to the revenue growth, with respective increases of 34% and 20% [5] - The chikungunya vaccine generated DKK 85 million in its first year of sales, exceeding guidance by DKK 10 million [5] 2026 Financial Guidance - For 2026, Bavarian Nordic expects revenue between DKK 5,000 million and DKK 5,200 million, with an EBITDA margin of approximately 25% [6][7] - Revenue from Public Preparedness is anticipated to be between DKK 1,800 million and DKK 2,000 million, with DKK 1,300 million already secured through contracts [8] - Travel Health revenue is projected at approximately DKK 3,000 million, reflecting a 10% growth over the prior year [9][10] Research and Development - R&D spending for 2026 is capped at DKK 750 million, focusing on life-cycle management of the commercial portfolio and additional studies for the chikungunya vaccine [11] - Early-stage pipeline assets are expected to enter clinical development in 2027 [11] Capital Expenditure - CAPEX for 2026 is expected to be around DKK 250 million, with inventory levels anticipated to remain relatively unchanged [12]

Core Viewpoint - Bavarian Nordic A/S has established a long-term incentive program for Executive Management and selected employees, which includes performance restricted stock units (Performance RSUs) and a warrant program as part of its Remuneration Policy [1][8]. Group 1: Performance Restricted Stock Units (Performance RSUs) - A total of 104,009 Performance RSUs are granted to members of Executive Management, with the value equating to up to 100% of their fixed annual base wage at the date of grant [2]. - Each Performance RSU is valued at DKK 188.26, based on the average market price of the company's shares on Nasdaq Copenhagen over a 15-business-day period prior to the grant [3]. - The Performance RSUs will vest in three years, contingent upon meeting specific Key Performance Indicators (KPIs) set by the Board of Directors [2]. Group 2: Warrant Program - A total of 1,270,820 warrants are granted to selected employees, allowing them to subscribe for up to 1,270,820 shares at a nominal value of DKK 10 each [4]. - The subscription price for the warrants is set at DKK 216.50 per share, which is the average market price plus a 15% premium over a 15-business-day period prior to the grant [4]. - The value of each warrant is calculated at DKK 69.52 using the Black-Scholes model, based on a share price of DKK 188.00 and a risk-free interest rate of 2.0% [5].

Core Points - Bavarian Nordic A/S has appointed Ms. Heidi Hunter as the new Vice Chair of the Board of Directors following the appointment of Anne Louise Eberhard as the new Chair [1][3] - Ms. Hunter has over 25 years of experience in the pharmaceutical industry, having held senior leadership roles at various companies including Cardinal Health, UCB, and Boehringer Ingelheim [2][3] - The Board is actively searching for additional candidates with relevant competencies to be nominated for election at the annual general meeting in April 2026 [3] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health and saving lives through innovative vaccines [4] - The company is a preferred supplier of mpox and smallpox vaccines to governments, enhancing public health preparedness, and has a leading portfolio of travel vaccines [4]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Group 1 - The article does not provide any specific content related to company or industry analysis [1]

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Points - Bavarian Nordic A/S announced the immediate resignation of Chair of the Board, Luc Debruyne, with Vice Chair Anne Louise Eberhard appointed as the new Chair [1][2] - Luc Debruyne expressed gratitude for the company's achievements during his tenure and emphasized the need for the board to focus on the next phase of development [2] - Anne Louise Eberhard acknowledged Debruyne's contributions and highlighted the importance of stability and continuity in governance as the company continues its growth trajectory [3] Company Overview - Bavarian Nordic is a global vaccine company dedicated to improving health and saving lives through innovative vaccines, including mpox and smallpox vaccines [4]

Core Insights - Bavarian Nordic A/S has clarified its recent agreement with the Health Emergency Preparedness and Response Authority (HERA) regarding public preparedness initiatives [1][4] - The company has received an initial order for 750,000 doses of the MVA-BN smallpox/mpox vaccine, which will be delivered in 2026 as part of a joint procurement contract by the European Commission through HERA [2] - This order follows a previous contract option awarded by the Biomedical Advanced Research and Development Authority (BARDA) in the U.S., indicating a strong start to building a preparedness business valued at DKK 1.5-2 billion for 2026 [2] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health and saving lives through innovative vaccines, particularly in the areas of mpox and smallpox [3] - The company is recognized as a preferred supplier of vaccines to governments, enhancing public health preparedness and maintaining a leading portfolio of travel vaccines [3]

Core Viewpoint - Innosera ApS has published a third supplement to its offer document, lowering the minimum acceptance condition for its takeover bid of Bavarian Nordic A/S from 75% to 66 2/3% of the voting rights and share capital [2][4]. Offer Details - The offer period has been extended, with the expiry time changed from 5:00 p.m. (CET) to 11:59 p.m. (CET) on November 5, 2025 [3]. - All other terms and conditions of the offer remain unchanged as per the previous supplements [4]. Shareholder Response - Institutional shareholders representing approximately 5.3% of Bavarian Nordic's share capital have committed to accept the improved offer during the extended period [5]. - As of October 21, 2025, the Offeror has received acceptances and binding commitments indicating a preliminary acceptance level of approximately 36.1% [5]. Regulatory Approval - The third supplement has been approved by the Danish Financial Supervisory Authority [6].